Christian M. Lange
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian M. Lange has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
S. Zeuzem
FIOCRUZ Viral Hepatitis Laboratory Institute Oswaldo Cruz
2 shared publicationsStefan Zeuzem
Medizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt, Germany
2 shared publicationsA J De Almeida
FIOCRUZ Viral Hepatitis Laboratory Institute Oswaldo Cruz
1 shared publicationAlina Bauschen
Department of Internal Medicine II, LMU University Hospital
1 shared publicationAndreas Cerny
Liver Unit, Ospedale Moncucco, Lugano, Switzerland
1 shared publication- Ann D. Kwong
Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139, USA
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1893968
APASL-ACLF without previous decompensation is immunologically distinct from EASL-CLIF-ACLF with previous decompensation
Background and aims: Definitions of acute-on-chronic liver failure (ACLF) differ, with a focus on extrahepatic organ failures on the basis of previously compensated or decompensated cirrhosis in EASL-CLIF-ACLF versus hepatic failure in patients without previous decompensation in APASL-ACLF. Here, we explored whether patterns of systemic inflammation and immune cell alterations differ between these types of ACLF. Methods: Consecutive patients with acute decompensation, EASL-CLIF- or APASL-ACLF were recruited from two liver centres. Patterns of systemic inflammation were characterized by Olink analysis and changes in circulating immune cells by flow cytometry. Results: A total of 374 patients with acute decompensation (AD) were identified, of whom 56 fulfilled exclusively the EASL-CLIF-definition of ACLF (15% of all patients), while only 19 patients (5.1% of all patients) met exclusively the APASL-definition. APASL-ACLF was associated with higher bilirubin, lower creatinine, higher INR and higher hemoglobin concentrations compared to EASL-ACLF. Patterns of systemic inflammation differed between EASL-CLIF and APASL-ACLF. For example, FGF-23, IL-17 or VEGF-A were associated with EASL-CLIF-ACLF, while FGF-19 or low IL-12 were associated with APASL-ACLF. Moreover, patients with EASL-CLIF-ACLF had significantly lower counts of CD8+ T cells, while in APASL-ACLF a reduction of CD4+ T cell was characteristic. Detailed immune cell phenotyping revealed distinct expression of co-stimulatory molecules, inhibitory molecules and T cell activation markers in APASL-ACLF compared to patients with AD or EASL-CLIF-ACLF. Conclusion: We provide preliminary evidence that EASL-CLIF- and APASL-ACLF are associated with different changes in systemic inflammation patterns and immune cell phenotypes, suggesting that both types of ACLF might be pathophysiologically different.
- 6 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1893968
Open AccessAPASL-ACLF without previous decompensation is immunologically distinct from EASL-CLIF-ACLF with previous decompensation
Background and aims: Definitions of acute-on-chronic liver failure (ACLF) differ, with a focus on extrahepatic organ failures on the basis of previously compensated or decompensated cirrhosis in EASL-CLIF-ACLF versus hepatic failure in patients without previous decompensation in APASL-ACLF. Here, we explored whether patterns of systemic inflammation and immune cell alterations differ between these types of ACLF. Methods: Consecutive patients with acute decompensation, EASL-CLIF- or APASL-ACLF were recruited from two liver centres. Patterns of systemic inflammation were characterized by Olink analysis and changes in circulating immune cells by flow cytometry. Results: A total of 374 patients with acute decompensation (AD) were identified, of whom 56 fulfilled exclusively the EASL-CLIF-definition of ACLF (15% of all patients), while only 19 patients (5.1% of all patients) met exclusively the APASL-definition. APASL-ACLF was associated with higher bilirubin, lower creatinine, higher INR and higher hemoglobin concentrations compared to EASL-ACLF. Patterns of systemic inflammation differed between EASL-CLIF and APASL-ACLF. For example, FGF-23, IL-17 or VEGF-A were associated with EASL-CLIF-ACLF, while FGF-19 or low IL-12 were associated with APASL-ACLF. Moreover, patients with EASL-CLIF-ACLF had significantly lower counts of CD8+ T cells, while in APASL-ACLF a reduction of CD4+ T cell was characteristic. Detailed immune cell phenotyping revealed distinct expression of co-stimulatory molecules, inhibitory molecules and T cell activation markers in APASL-ACLF compared to patients with AD or EASL-CLIF-ACLF. Conclusion: We provide preliminary evidence that EASL-CLIF- and APASL-ACLF are associated with different changes in systemic inflammation patterns and immune cell phenotypes, suggesting that both types of ACLF might be pathophysiologically different.
- 20 January 2015
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 47 (S 01) , E531
Combined percutaneous retrograde and peroral antegrade esophagoscopy for the treatment of complete upper esophageal obstruction
Complete upper esophageal obstruction is a rare but significant complication of, for example, radiotherapy or caustic ingestion. It may be resolved by endoscopic techniques [1] [2] [3] [4]. Here, we report three patients with complete or nearly complete upper esophageal obstruction after curative radiochemotherapy for head and neck cancers, in whom classic peroral insertion of a guidewire for esophageal dilation failed. However, in all of these patients, esophageal stenosis was successfully treated by the combinination of a percutaneous retrograde and a peroral antegrade endoscopic approach. The length of the stenoses in these patients ranged from 2 to 20 mm ([Fig. 1]). Retrograde esophagoscopy was accomplished with an ultraslim gastroscope through an existing percutaneous gastrostomy. At the same time, peroral antegrade esophagoscopy was performed to enable diaphanoscopy-guided recanalization of the esophageal stenosis with a needle knife ( [Fig. 1], [Video 1]). Afterward, a stomach tube was placed, and the reconstructed esophageal neolumen was allowed to heal for 2 to 4 weeks. Subsequently, the patients have undergone conventional esophageal dilation procedures, which have been ongoing for 4 to 24 months ([Fig. 1]). Meanwhile, all the patients can be nourished orally and have experienced a significant increase in body weight and improvement in quality of life. No relevant complications have been observed in these patients during the entire course of endoscopic treatment. In conclusion, the combination of a percutaneous retrograde and a peroral antegrade endoscopic approach can be safe and efficient for the treatment of complete upper esophageal stenosis. Endoscopy_UCTN_Code_TTT_1AO_2AD
- 20 January 2015
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 47 (S 01) , E531
Combined percutaneous retrograde and peroral antegrade esophagoscopy for the treatment of complete upper esophageal obstruction
Complete upper esophageal obstruction is a rare but significant complication of, for example, radiotherapy or caustic ingestion. It may be resolved by endoscopic techniques [1] [2] [3] [4]. Here, we report three patients with complete or nearly complete upper esophageal obstruction after curative radiochemotherapy for head and neck cancers, in whom classic peroral insertion of a guidewire for esophageal dilation failed. However, in all of these patients, esophageal stenosis was successfully treated by the combinination of a percutaneous retrograde and a peroral antegrade endoscopic approach. The length of the stenoses in these patients ranged from 2 to 20 mm ([Fig. 1]). Retrograde esophagoscopy was accomplished with an ultraslim gastroscope through an existing percutaneous gastrostomy. At the same time, peroral antegrade esophagoscopy was performed to enable diaphanoscopy-guided recanalization of the esophageal stenosis with a needle knife ( [Fig. 1], [Video 1]). Afterward, a stomach tube was placed, and the reconstructed esophageal neolumen was allowed to heal for 2 to 4 weeks. Subsequently, the patients have undergone conventional esophageal dilation procedures, which have been ongoing for 4 to 24 months ([Fig. 1]). Meanwhile, all the patients can be nourished orally and have experienced a significant increase in body weight and improvement in quality of life. No relevant complications have been observed in these patients during the entire course of endoscopic treatment. In conclusion, the combination of a percutaneous retrograde and a peroral antegrade endoscopic approach can be safe and efficient for the treatment of complete upper esophageal stenosis. Endoscopy_UCTN_Code_TTT_1AO_2AD
- Open Access
- 29 May 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e64053
Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development
Vitamin D insufficiency has been associated with the occurrence of various types of cancer, but causal relationships remain elusive. We therefore aimed to determine the relationship between genetic determinants of vitamin D serum levels and the risk of developing hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Associations between CYP2R1, GC, and DHCR7 genotypes that are determinants of reduced 25-hydroxyvitamin D (25[OH]D3) serum levels and the risk of HCV-related HCC development were investigated for 1279 chronic hepatitis C patients with HCC and 4325 without HCC, respectively. The well-known associations between CYP2R1 (rs1993116, rs10741657), GC (rs2282679), and DHCR7 (rs7944926, rs12785878) genotypes and 25(OH)D3 serum levels were also apparent in patients with chronic hepatitis C. The same genotypes of these single nucleotide polymorphisms (SNPs) that are associated with reduced 25(OH)D3 serum levels were found to be associated with HCV-related HCC (P = 0.07 [OR = 1.13, 95% CI = 0.99–1.28] for CYP2R1, P = 0.007 [OR = 1.56, 95% CI = 1.12–2.15] for GC, P = 0.003 [OR = 1.42, 95% CI = 1.13–1.78] for DHCR7; ORs for risk genotypes). In contrast, no association between these genetic variations and liver fibrosis progression rate (P>0.2 for each SNP) or outcome of standard therapy with pegylated interferon-α and ribavirin (P>0.2 for each SNP) was observed, suggesting a specific influence of the genetic determinants of 25(OH)D3 serum levels on hepatocarcinogenesis. Our data suggest a relatively weak but functionally relevant role for vitamin D in the prevention of HCV-related hepatocarcinogenesis.
- 29 May 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (5) , e64053
Open AccessGenetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development
Vitamin D insufficiency has been associated with the occurrence of various types of cancer, but causal relationships remain elusive. We therefore aimed to determine the relationship between genetic determinants of vitamin D serum levels and the risk of developing hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Associations between CYP2R1, GC, and DHCR7 genotypes that are determinants of reduced 25-hydroxyvitamin D (25[OH]D3) serum levels and the risk of HCV-related HCC development were investigated for 1279 chronic hepatitis C patients with HCC and 4325 without HCC, respectively. The well-known associations between CYP2R1 (rs1993116, rs10741657), GC (rs2282679), and DHCR7 (rs7944926, rs12785878) genotypes and 25(OH)D3 serum levels were also apparent in patients with chronic hepatitis C. The same genotypes of these single nucleotide polymorphisms (SNPs) that are associated with reduced 25(OH)D3 serum levels were found to be associated with HCV-related HCC (P = 0.07 [OR = 1.13, 95% CI = 0.99–1.28] for CYP2R1, P = 0.007 [OR = 1.56, 95% CI = 1.12–2.15] for GC, P = 0.003 [OR = 1.42, 95% CI = 1.13–1.78] for DHCR7; ORs for risk genotypes). In contrast, no association between these genetic variations and liver fibrosis progression rate (P>0.2 for each SNP) or outcome of standard therapy with pegylated interferon-α and ribavirin (P>0.2 for each SNP) was observed, suggesting a specific influence of the genetic determinants of 25(OH)D3 serum levels on hepatocarcinogenesis. Our data suggest a relatively weak but functionally relevant role for vitamin D in the prevention of HCV-related hepatocarcinogenesis.
- 5 August 2011
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 46 (11) , 1362-1368
HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a
Background. The extensive heterogeneity of the hypervariable region-1 (HVR-1) of hepatitis C virus (HCV) evidences the high genetic flexibility of HCV and was shown to be associated with virologic response to interferon-α-based therapies. However, the evolution of HVR-1 heterogeneity during treatment with directly acting antivirals has not been studied. Methods. Clonal sequence analysis of HVR-1 quasispecies in the serum of patients who were treated with telaprevir (3 × 750 mg/day) alone, telaprevir plus pegylated interferon-α-2a (pegIFN-α-2a), or pegIFN-α-2a plus placebo for 14 days was performed. HVR-1 heterogeneity, expressed as Shannon complexity and Hamming distance, was analyzed with virologic response and with the emergence of variants associated with resistance to telaprevir. Results. HVR-1 heterogeneity at baseline was not associated with response to telaprevir-based therapy (Shannon complexity 0.34 vs. 0.55, p = 0.38; Hamming distance 0.15 vs. 0.23, p = 0.51; for patients with or without viral breakthrough, respectively). No significant changes in HVR-1 complexity were observed from baseline to day 4 of therapy in patients in whom a continued decline in HCV RNA was observed (Shannon complexity = 0.55 vs. 0.51, p = 0.67; Hamming distance = 0.23 vs. 0.25, p = 0.81, respectively). This was similar in patients with viral breakthrough associated with telaprevir-resistant variants (Shannon complexity = 0.34 vs. 0.42, p = 0.68; Hamming distance = 0.15 vs. 0.2, p = 0.50, at baseline and day 4, respectively). Conclusions. Baseline and on-treatment HVR-1 heterogeneity are not associated with early viral response to telaprevir-based therapy.
- 5 August 2011
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 46 (11) , 1362-1368
HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a
Background. The extensive heterogeneity of the hypervariable region-1 (HVR-1) of hepatitis C virus (HCV) evidences the high genetic flexibility of HCV and was shown to be associated with virologic response to interferon-α-based therapies. However, the evolution of HVR-1 heterogeneity during treatment with directly acting antivirals has not been studied. Methods. Clonal sequence analysis of HVR-1 quasispecies in the serum of patients who were treated with telaprevir (3 × 750 mg/day) alone, telaprevir plus pegylated interferon-α-2a (pegIFN-α-2a), or pegIFN-α-2a plus placebo for 14 days was performed. HVR-1 heterogeneity, expressed as Shannon complexity and Hamming distance, was analyzed with virologic response and with the emergence of variants associated with resistance to telaprevir. Results. HVR-1 heterogeneity at baseline was not associated with response to telaprevir-based therapy (Shannon complexity 0.34 vs. 0.55, p = 0.38; Hamming distance 0.15 vs. 0.23, p = 0.51; for patients with or without viral breakthrough, respectively). No significant changes in HVR-1 complexity were observed from baseline to day 4 of therapy in patients in whom a continued decline in HCV RNA was observed (Shannon complexity = 0.55 vs. 0.51, p = 0.67; Hamming distance = 0.23 vs. 0.25, p = 0.81, respectively). This was similar in patients with viral breakthrough associated with telaprevir-resistant variants (Shannon complexity = 0.34 vs. 0.42, p = 0.68; Hamming distance = 0.15 vs. 0.2, p = 0.50, at baseline and day 4, respectively). Conclusions. Baseline and on-treatment HVR-1 heterogeneity are not associated with early viral response to telaprevir-based therapy.
- Open Access
- 1 March 2011
- Published by Elsevier in Journal of Hepatology
- Vol. 54, S180-S181
444 SVR FOR CONTROLLED-RELEASE INTERFERON ALPHA-2B (CR2B) +RIBAVIRIN COMPARED TO PEGYLATED INTERFERON ALPHA-2B (PEG2B) +RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 (G1) HEPATITIS C: FINAL RESULTS FROM SELECT-2
- 1 March 2011
- Published by Elsevier in Journal of Hepatology
- Vol. 54, S180-S181
Open Access444 SVR FOR CONTROLLED-RELEASE INTERFERON ALPHA-2B (CR2B) +RIBAVIRIN COMPARED TO PEGYLATED INTERFERON ALPHA-2B (PEG2B) +RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 (G1) HEPATITIS C: FINAL RESULTS FROM SELECT-2
- Open Access
- 1 March 2011
- Published by Elsevier in Journal of Hepatology
- Vol. 54, S180
443 VITAMIN D DEFICIENCY IS FREQUENT IN CHRONIC HEPATITIS C AND AFFECTS THE OUTCOME OF INTERFERON-ALFA BASED THERAPY
- 1 March 2011
- Published by Elsevier in Journal of Hepatology
- Vol. 54, S180
Open Access443 VITAMIN D DEFICIENCY IS FREQUENT IN CHRONIC HEPATITIS C AND AFFECTS THE OUTCOME OF INTERFERON-ALFA BASED THERAPY
- 6 October 2009
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 47 (10) , 1062-1064
Primary Actinomycosis of the Liver Mimicking Malignancy
Wir berichten den Fall einer 71-jährigen Patientin, die sich mit Fieber, Gewichtsverlust, Nachtschweiß und Oberbauchschmerzen bestehend seit etwa 6 Monaten vorstellte. Die Abdomen-Sonografie und Magnetresonanztomografie zeigten eine irregulär geformte, inhomogene und hypointense Läsion im rechten Leberlappen (6 × 8 cm Segment 7 und 8) mit multiplen Satellitenherden. Die irreguläre Form, die hypovaskuläre Präsentation in der Gadolinium-Kontrastphase, das hypointense Signalverhalten in den T 1-gewichteten Bildern sowie eine intrahepatische Cholestase waren hochgradig suggestiv für das Vorliegen eines Cholangiokarzinoms oder einer Lebermetastase. Die Histologie offenbarte jedoch eine seltene Aktinomykose der Leber, die erfolgreich mit Antibiotika therapiert werden konnte. A 71-year old women presented with fever, a significant loss of body weight and abdominal pain in the upper right quadrant since approximately six months. Abdominal ultrasonography and magnetic resonance imaging (MRI) showed an irregularly shaped, inhomogeneous and hypointense lesion of the right liver lobe (6 × 8 cm in segment 7 and 8) with multiple satellite lesions. Irregular shape, hypovascular presentation during gadolinium enhancement, hypointensity in T 1-weighted images and dilation of peripheral bile ducts were suggestive for cholangiocarcinoma or metastasis. However, histological investigations revealed a rare case of primary actinomycosis of the liver which was successfully treated with antibiotics.
- 6 October 2009
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 47 (10) , 1062-1064
Primary Actinomycosis of the Liver Mimicking Malignancy
Wir berichten den Fall einer 71-jährigen Patientin, die sich mit Fieber, Gewichtsverlust, Nachtschweiß und Oberbauchschmerzen bestehend seit etwa 6 Monaten vorstellte. Die Abdomen-Sonografie und Magnetresonanztomografie zeigten eine irregulär geformte, inhomogene und hypointense Läsion im rechten Leberlappen (6 × 8 cm Segment 7 und 8) mit multiplen Satellitenherden. Die irreguläre Form, die hypovaskuläre Präsentation in der Gadolinium-Kontrastphase, das hypointense Signalverhalten in den T 1-gewichteten Bildern sowie eine intrahepatische Cholestase waren hochgradig suggestiv für das Vorliegen eines Cholangiokarzinoms oder einer Lebermetastase. Die Histologie offenbarte jedoch eine seltene Aktinomykose der Leber, die erfolgreich mit Antibiotika therapiert werden konnte. A 71-year old women presented with fever, a significant loss of body weight and abdominal pain in the upper right quadrant since approximately six months. Abdominal ultrasonography and magnetic resonance imaging (MRI) showed an irregularly shaped, inhomogeneous and hypointense lesion of the right liver lobe (6 × 8 cm in segment 7 and 8) with multiple satellite lesions. Irregular shape, hypovascular presentation during gadolinium enhancement, hypointensity in T 1-weighted images and dilation of peripheral bile ducts were suggestive for cholangiocarcinoma or metastasis. However, histological investigations revealed a rare case of primary actinomycosis of the liver which was successfully treated with antibiotics.
- 26 June 2007
- Published by Wiley in Immunology & Cell Biology
- Vol. 85 (8) , 575-581
Dendritic cell–regulatory T‐cell interactions control self‐directed immunity
In addition to their immunostimulatory capacity, dendritic cells (DCs) play a crucial role in central and peripheral tolerance mechanisms. In the absence of an infection, immature DCs constantly take up, process and present self‐antigens to specific T cells, which leads to the induction of T‐cell anergy or deletion. In recent years, several additional mechanisms have been identified by which DCs constantly downregulate immune responses to maintain immunological tolerance. Among these are the complex interactions between several DC subtypes and different types of regulatory T cells. In this review, we summarize recent key findings and concepts in this field.
- 26 June 2007
- Published by Wiley in Immunology & Cell Biology
- Vol. 85 (8) , 575-581
Dendritic cell–regulatory T‐cell interactions control self‐directed immunity
In addition to their immunostimulatory capacity, dendritic cells (DCs) play a crucial role in central and peripheral tolerance mechanisms. In the absence of an infection, immature DCs constantly take up, process and present self‐antigens to specific T cells, which leads to the induction of T‐cell anergy or deletion. In recent years, several additional mechanisms have been identified by which DCs constantly downregulate immune responses to maintain immunological tolerance. Among these are the complex interactions between several DC subtypes and different types of regulatory T cells. In this review, we summarize recent key findings and concepts in this field.